JP2018531260A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531260A5
JP2018531260A5 JP2018519382A JP2018519382A JP2018531260A5 JP 2018531260 A5 JP2018531260 A5 JP 2018531260A5 JP 2018519382 A JP2018519382 A JP 2018519382A JP 2018519382 A JP2018519382 A JP 2018519382A JP 2018531260 A5 JP2018531260 A5 JP 2018531260A5
Authority
JP
Japan
Prior art keywords
genetically engineered
hematopoietic cell
human hematopoietic
engineered human
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519382A
Other languages
English (en)
Japanese (ja)
Other versions
JP7017506B2 (ja
JP2018531260A6 (ja
JP2018531260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/057339 external-priority patent/WO2017066760A1/en
Publication of JP2018531260A publication Critical patent/JP2018531260A/ja
Publication of JP2018531260A6 publication Critical patent/JP2018531260A6/ja
Publication of JP2018531260A5 publication Critical patent/JP2018531260A5/ja
Priority to JP2022010861A priority Critical patent/JP7680384B2/ja
Application granted granted Critical
Publication of JP7017506B2 publication Critical patent/JP7017506B2/ja
Priority to JP2024205201A priority patent/JP2025028963A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519382A 2015-10-16 2016-10-17 系統特異的抗原の阻害のための組成物および方法 Active JP7017506B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022010861A JP7680384B2 (ja) 2015-10-16 2022-01-27 系統特異的抗原の阻害のための組成物および方法
JP2024205201A JP2025028963A (ja) 2015-10-16 2024-11-26 系統特異的抗原の阻害のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562242685P 2015-10-16 2015-10-16
US62/242,685 2015-10-16
PCT/US2016/057339 WO2017066760A1 (en) 2015-10-16 2016-10-17 Compositions and methods for inhibition of lineage specific antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022010861A Division JP7680384B2 (ja) 2015-10-16 2022-01-27 系統特異的抗原の阻害のための組成物および方法

Publications (4)

Publication Number Publication Date
JP2018531260A JP2018531260A (ja) 2018-10-25
JP2018531260A6 JP2018531260A6 (ja) 2018-12-13
JP2018531260A5 true JP2018531260A5 (cg-RX-API-DMAC7.html) 2019-11-28
JP7017506B2 JP7017506B2 (ja) 2022-02-08

Family

ID=58518249

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018519382A Active JP7017506B2 (ja) 2015-10-16 2016-10-17 系統特異的抗原の阻害のための組成物および方法
JP2022010861A Active JP7680384B2 (ja) 2015-10-16 2022-01-27 系統特異的抗原の阻害のための組成物および方法
JP2024205201A Ceased JP2025028963A (ja) 2015-10-16 2024-11-26 系統特異的抗原の阻害のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022010861A Active JP7680384B2 (ja) 2015-10-16 2022-01-27 系統特異的抗原の阻害のための組成物および方法
JP2024205201A Ceased JP2025028963A (ja) 2015-10-16 2024-11-26 系統特異的抗原の阻害のための組成物および方法

Country Status (10)

Country Link
US (7) US10137155B2 (cg-RX-API-DMAC7.html)
EP (2) EP4265633A3 (cg-RX-API-DMAC7.html)
JP (3) JP7017506B2 (cg-RX-API-DMAC7.html)
CN (2) CN116712535A (cg-RX-API-DMAC7.html)
AU (2) AU2016337525B2 (cg-RX-API-DMAC7.html)
CA (1) CA3001859A1 (cg-RX-API-DMAC7.html)
ES (1) ES2962651T3 (cg-RX-API-DMAC7.html)
IL (3) IL258491B2 (cg-RX-API-DMAC7.html)
MX (2) MX2018004546A (cg-RX-API-DMAC7.html)
WO (1) WO2017066760A1 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201606B2 (en) 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
EP3370741B1 (en) 2015-11-04 2025-10-08 The Trustees of the University of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102709603B1 (ko) * 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
EP3676372A4 (en) * 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33
KR102320280B1 (ko) * 2018-05-31 2021-11-29 주식회사 센트릭스바이오 CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
KR20210046001A (ko) * 2018-08-21 2021-04-27 시그마-알드리치 컴퍼니., 엘엘씨 시토졸 dna 센서 경로의 하향-조절
WO2020051013A2 (en) * 2018-08-24 2020-03-12 The Trustees Of Columbia University In The City Of New York Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies
CA3110837A1 (en) * 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
JP2022513338A (ja) * 2018-10-03 2022-02-07 ネペンザ・バイオサイエンシズ・エルエルシー 抗cd79抗体およびその使用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
JP7784707B2 (ja) * 2019-01-16 2025-12-12 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 系統特異的抗原の阻害のための組成物および方法
TWI870378B (zh) 2019-01-28 2025-01-21 大陸商沐特圖公司 Cd44特異性抗體
CN109777784B (zh) * 2019-02-22 2021-12-31 上海尚泰生物技术有限公司 一种增强向肿瘤部位迁移的嵌合抗原受体载体构建方法与应用
AU2020280103A1 (en) 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
US20220251192A1 (en) * 2019-06-26 2022-08-11 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
AU2020338011A1 (en) 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
WO2021041977A1 (en) 2019-08-28 2021-03-04 Vor Biopharma, Inc. Compositions and methods for cd123 modification
EP4048790A4 (en) * 2019-10-22 2024-03-27 Fred Hutchinson Cancer Center BASE EDITOR-MEDIATED CD33 REDUCTION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
US12616734B2 (en) 2019-11-28 2026-05-05 CentricsBio, Inc. Chimeric antigen receptor specifically binding to cd 300C antigen or receptor thereof
EP4121462A4 (en) * 2020-03-16 2024-04-24 Magenta Therapeutics, Inc. BISPECIFIC T CELL BINDING PROTEINS
CN116157135A (zh) * 2020-06-03 2023-05-23 纽约市哥伦比亚大学理事会 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法
EP4204564A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cd123 modification
EP4204565A1 (en) 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cll1 modification
EP4211245A1 (en) 2020-09-14 2023-07-19 Vor Biopharma Inc. Compositions and methods for cd5 modification
EP4210832A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
WO2022056489A1 (en) 2020-09-14 2022-03-17 Vor Biopharma, Inc. Compositions and methods for cd38 modification
WO2022061115A1 (en) 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
WO2022067240A1 (en) 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification
WO2022072643A1 (en) 2020-09-30 2022-04-07 Vor Biopharma Inc. Compositions and methods for cd30 gene modification
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
CN116744963A (zh) * 2020-11-13 2023-09-12 Vor生物制药股份有限公司 与表达嵌合抗原受体的经基因工程化的细胞有关的方法和组合物
WO2022104090A1 (en) 2020-11-13 2022-05-19 Vor Biopharma Inc. Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
AU2021413252A1 (en) * 2020-12-31 2023-06-08 Vor Biopharma Inc. Compositions and methods for cd34 gene modification
CN115443333B (zh) * 2021-04-27 2025-04-25 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
EP4349858A4 (en) * 2021-05-24 2025-06-11 CentricsBio, Inc. CHIMERIC ANTIGEN RECEPTOR SPECIFICALLY BINDING TO THE CD300C ANTIGEN OR ITS RECEPTOR
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
WO2023010126A2 (en) 2021-07-29 2023-02-02 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
EP4381062A1 (en) 2021-08-02 2024-06-12 Vor Biopharma Inc. Compositions and methods for gene modification
US20240408234A1 (en) * 2021-09-14 2024-12-12 Vor Biopharma Inc. Compositions and methods for multiplex base editing in hematopoietic cells
EP4430186A1 (en) 2021-11-09 2024-09-18 Vor Biopharma Inc. Compositions and methods for erm2 modification
US20250295695A1 (en) 2022-04-04 2025-09-25 Vor Biopharma Inc. Compositions and methods for mediating epitope engineering
JP2025513855A (ja) 2022-04-11 2025-04-30 ブイオーアール バイオファーマ インコーポレーテッド 結合剤及びその使用方法
CN114778857B (zh) * 2022-06-17 2022-08-23 信纳克(北京)生化标志物检测医学研究有限责任公司 检测非造血系统肿瘤的试剂组合物及其应用
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
WO2024168312A1 (en) 2023-02-09 2024-08-15 Vor Biopharma Inc. Methods for treating hematopoietic malignancy
EP4713363A1 (en) 2023-05-15 2026-03-25 Syzygymed Inc Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
CN117946270B (zh) * 2023-12-26 2025-02-11 华润生物医药有限公司 抗cd93抗体及其用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE237694T1 (de) 1991-08-20 2003-05-15 Us Gov Health & Human Serv Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
WO1993025216A1 (en) * 1992-06-08 1993-12-23 Becton, Dickinson And Company Human primitive stem cells
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO INACTIVATION BY HUMAN SERUM.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5756910A (en) 1996-08-28 1998-05-26 Burgett, Inc. Method and apparatus for actuating solenoids in a player piano
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US20100172882A1 (en) 2007-01-11 2010-07-08 Glazer Peter M Compositions and methods for targeted inactivation of hiv cell surface receptors
CN101903403B (zh) 2007-10-19 2016-03-16 西雅图基因公司 Cd19结合剂及其应用
JP6073135B2 (ja) 2009-10-19 2017-02-01 トライステム・トレイディング・(キプロス)・リミテッドTriStem Trading (Cyprus) Limited 再プログラム化成熟成体細胞を用いる治療
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
ES2765710T3 (es) * 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
JP6831777B2 (ja) 2014-07-21 2021-02-17 ノバルティス アーゲー Cd33キメラ抗原受容体を使用する癌の処置
US10201606B2 (en) * 2014-11-26 2019-02-12 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CA2986310A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
EP3370741B1 (en) 2015-11-04 2025-10-08 The Trustees of the University of Pennsylvania Methods and compositions for gene editing in hematopoietic stem cells
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
EP3448995A1 (en) 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
US20190365806A1 (en) 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
EP3676372A4 (en) 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33

Similar Documents

Publication Publication Date Title
JP7168641B2 (ja) 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節
Tsao et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
Ruggeri et al. Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Battella et al. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
LTPA2022520I1 (cg-RX-API-DMAC7.html)
JP2022517618A5 (cg-RX-API-DMAC7.html)
PH12017501732A1 (en) Therapeutic antibodies and their uses
JP2018510881A5 (cg-RX-API-DMAC7.html)
JOP20190116A1 (ar) الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
PH12021551484A1 (en) Antibodies binding to cd3
HRP20171577T1 (hr) Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
JP2018508215A5 (cg-RX-API-DMAC7.html)
SG10201806293WA (en) Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
PH12021553254A1 (en) Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
AU2019277660A1 (en) Materials and methods for treating cancer
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
Bugide et al. Epigenetic mechanisms dictating eradication of cancer by natural killer cells
Chen et al. Natural killer cells: the next wave in cancer immunotherapy
JP2021500918A5 (cg-RX-API-DMAC7.html)
CN113194715A (zh) 用于治疗癌症的材料和方法
Balduzzi et al. Acute lymphoblastic leukaemia in the youngest: haematopoietic stem cell transplantation and beyond
Chen et al. Stereotactic ablative radiotherapy and FAPα-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer